Long-term ALS survival benefit with CNM-Au8 seen in trial analyses

Clene Nanomedicine Presents Clinical Data - Rehab Management

Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression

Restoration of function by CNM-Au8 in open field test and fine motor

Update on clinical trials - part 1 - MND Research Blog

Clene Nanomedicine, Inc. on LinkedIn: #als #cnmau8 #gold #nanocrystal #neurodegeneration

Clene Releases Significant Long-Term Survival Improvement Data from ALS Trial

MDA2022 – CNM-Au8 May Slow ALS Progression, Reduce Mortality Risk

/wp-content/uploads/2023/09/AI-Medic

Symposium Blogathon: Focus on Clinical Trial Updates (part 1) - MND Research Blog

ALS clinical trials and studies • Les Turner ALS Foundation

Long-term ALS survival benefit with CNM-Au8 seen in trial analyses, HEALEY ALS trial now tested therapy for up to 2.5 years in patients

Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension - eClinicalMedicine

Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development - Paganoni - 2022 - Annals of Neurology - Wiley Online Library

Synapticure on Science: Clinical Trials for Sporadic ALS

Neuromuscular Notes: New and Emerging Therapies in ALS - Practical Neurology